Peptides explained in plain language
Not medical advice
Research-only

Nootropic peptides: what Semax and Selank are

Two Russian-developed peptides are marketed online for focus and calm, but neither is approved in the U.S. and the evidence is thin.

Key takeaways

  • Semax and Selank were developed in Russia and aren't approved by the FDA.
  • An FDA advisory panel recommended Semax for compounding in July 2026, but that vote isn't a final decision.
  • Most of the research comes from small studies, and good U.S. data is lacking.
  • Products sold online as research chemicals have no guaranteed dose, purity or sterility.

“Nootropic” is a marketing word for anything said to sharpen thinking. Two peptides that often appear under that label are Semax and Selank. Both are usually sold online as nasal sprays or powders, with claims about focus, memory, mood or stress.

Here is what is known, and what isn’t.

Where they come from

Both peptides were developed in Russia. They are short, lab-made chains of amino acids based on fragments of natural molecules.

  • Semax is based on a small piece of a hormone made by the pituitary gland. It is usually promoted for focus and memory.
  • Selank is based on a small immune-related peptide. It is usually promoted for calm and anxiety.

Neither one is approved by the FDA for any use.

What the evidence looks like

Most of the published research comes from Russian labs, animal studies and small human studies. That doesn’t make it worthless, but it does mean the results haven’t been confirmed in large, independent trials of the kind FDA requires for approval.

So online claims that these peptides improve memory, mood or focus in healthy people go well beyond what has been shown. Long-term safety is also largely unknown.

Get the weekly peptide brief

What changed in the rules, what new research says, and which claims to ignore. One email a week.

Where things stand with FDA

The regulatory picture changed in 2026, and it is easy to misread.

  • In April 2026, FDA removed Semax from its list of compounding substances with significant safety risks. That happened because the nomination was withdrawn, not because of new safety findings.
  • In July 2026, an FDA advisory committee voted to recommend adding Semax to the list of substances pharmacies may use in compounding. FDA’s own staff had recommended against it.
  • That vote is advice only. FDA still has to act, and as of October 2026 there’s no final decision.
  • FDA’s safety-risk page lists the Selank nomination as withdrawn, and Selank wasn’t among the peptides the panel recommended.

In its review, FDA flagged that both peptides may pose a risk of unwanted immune reactions for some routes of use, due to clumping and impurities.

“Research use only” is a warning, not a credential. These products aren’t made to drug standards. The dose could be wrong, the vial could hold a different substance, and there is no recall system.

Questions worth asking

  • What problem am I actually trying to solve: sleep, stress, attention, mood?
  • Has a clinician checked for common causes, like poor sleep, thyroid problems or depression?
  • Are there approved treatments or proven habits that fit my goal?
  • Could a peptide interact with medicines I already take?

A clinician or pharmacist can help with these. Trouble focusing and ongoing anxiety are worth a real evaluation.

The bottom line

Semax and Selank are unapproved peptides with limited, mostly foreign research behind them. A July 2026 panel vote raised Semax’s profile, but nothing is final. If you’re struggling with focus or stress, start with a clinician rather than a vial from a website.

This article is for general education and isn’t medical or legal advice. It was written with AI assistance and may contain errors, so check anything that matters against the sources above and with a qualified healthcare professional before starting, stopping or changing any treatment. Why we say this.

Chris Janowski
About the author

Chris Janowski, owner and editor in chief

Chris Janowski is the editor in chief of Peptide Consumer Center. He started the site to give people a plain-language, well-sourced place to learn what peptides are, how they’re regulated and what the evidence actually says. Articles are written with AI assistance and published under his name.

Peptide Consumer Center is owned by Chris Janowski, who also owns PureVitaX, an online store that sells peptides, including several covered on this site. We link to PureVitaX, and Chris benefits when you buy there. Disclosures.